Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
-
Publication number: 20140255990Abstract: The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicant: Arizona Board of RegentsInventors: John Chaput, Bertram Jacobs, Brian Wellensiek, Julia Flores
-
Patent number: 8829177Abstract: We describe methods and DNA constructs/engineered mammalian promoters to enhance native promoter activity while retaining inherent regulation by inserting multi-copy response elements (REs) into non-adjacent locations. Multiple copies of REs are clustered in a group forming a transcription factor response element segment. The segment is at least duplicated in tandem upstream of the ATG start codon. Spacers of 0.2-0.7 kilo base pairs are introduced between the two segments and smaller spacers of about between 9-15 bp are introduced between the copies of REs within a segment.Type: GrantFiled: June 5, 2010Date of Patent: September 9, 2014Assignee: The General Hospital CorporationInventors: David B. Rhoads, Jianmin Huang, Lynne L. Levitsky
-
Patent number: 8829272Abstract: The present invention relates generally to methods and transcriptional control sequences suitable for effecting expression of a nucleotide sequence of interest in a plant. More particularly, the present invention relates to methods and transcriptional control sequences suitable for directing specific or preferential expression of a nucleotide sequence of interest in a plant seed. Of particular interest as a transcriptional control sequence in this invention is the promoter PR602 (SEQ ID NO: 1) found in the 5?-untranslated region of the rice END1-like gene and isolated from a rice panicle library.Type: GrantFiled: October 27, 2006Date of Patent: September 9, 2014Assignees: Adelaide Research & Innovation Pty Ltd, Grains Research & Development CorporationInventors: Sergiy Lopato, Ming Li
-
Patent number: 8829176Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.Type: GrantFiled: July 15, 2008Date of Patent: September 9, 2014Assignee: Genzyme CorporationInventors: Scott D. Estes, Weiqun Zhang
-
Patent number: 8828961Abstract: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.Type: GrantFiled: October 19, 2011Date of Patent: September 9, 2014Assignee: HarrisvaccinesInventors: John Dustin Loy, Lyric Colleen Bartholomay, Delbert Linn Harris, Ed Scura, Kurt Iver Kamrud
-
Patent number: 8828959Abstract: A pharmaceutical composition that blocks angiogenesis comprising as active agent at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid molecule according to (i).Type: GrantFiled: March 18, 2008Date of Patent: September 9, 2014Assignee: Gene Signal International SAInventor: Salman Al-Mahmood
-
Patent number: 8829173Abstract: This disclosure provides recombinant replication competent retroviral vectors having increased stability. The disclosure further relates compositions and uses of such vectors in the treatment of disease and disorders.Type: GrantFiled: March 26, 2011Date of Patent: September 9, 2014Assignee: Tocagen Inc.Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
-
Patent number: 8828962Abstract: No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of ?-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.Type: GrantFiled: December 12, 2011Date of Patent: September 9, 2014Assignee: Xiangxue Group (Hong Kong) Company LimitedInventors: Bojian Zheng, Hongyan Sui, Yongping Lin
-
Patent number: 8828658Abstract: The invention provides methods, materials and systems of regulating association between proteins of interest using light. In an aspect, the invention takes advantage of the ability of phytochromes to change conformation upon exposure to appropriate light conditions, and to bind in a conformation-dependent manner to cognate proteins called phytochrome-interacting factors. The invention comprises a method of regulating interaction between a first protein of interest and second protein within a cell by light. Such a method optionally comprises providing in the cell (1) a first protein construct which comprises the first protein, a phytochrome domain (PHD), and (2) providing in the cell a second protein construct which comprises the second protein and a phytochrome domain-interacting peptide (PIP) that can bind selectively to the Pfr state, but not to the Pr state, of the phytochrome domain.Type: GrantFiled: May 26, 2009Date of Patent: September 9, 2014Assignee: The Regents of the University of CaliforniaInventors: Christopher A. Voigt, Anselm Levskaya, Wendell Lim
-
Publication number: 20140248701Abstract: Isolated polynucleotides comprising a DCX mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.Type: ApplicationFiled: January 23, 2014Publication date: September 4, 2014Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra, Charles de Leeuw
-
Publication number: 20140250546Abstract: The invention relates to efficient, high-throughput methods, systems, and DNA constructs for identification and isolation of terminator sequences causing enhanced transcription. The invention further relates to terminator sequences isolated with such methods and their use for enhancing gene expression.Type: ApplicationFiled: July 20, 2012Publication date: September 4, 2014Applicant: BASF PLANT SCIENCE COMPANY GMBHInventors: Julia Verena Hartig, Alrun Nora Burgmeier, Josef Martin Kuhn, Linda Patricia Loyall, Elke Duwenig
-
Publication number: 20140249303Abstract: The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of developing ulcerative colitis was shown to be correlated with the presence of an ATTG insertion/deletion in the NFKB1 promoter and is likely to apply also to a variety of other inflammatory diseases.Type: ApplicationFiled: October 4, 2013Publication date: September 4, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Steven R. Brant, Amir Karban, Franklin Nouvet, Theodore M. Bayless, James J. Potter, Esteban Mezey, Toshihiko Okazaki
-
Publication number: 20140248309Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.Type: ApplicationFiled: February 20, 2014Publication date: September 4, 2014Applicant: Government of the U.S.A, as represented by the Secretary, Dept. of Health & Human SInventors: DENNIS J. KOPECKO, MANUEL OSORIO, SIBA BHATTACHARYYA, CHANDRAKANT P. GIRI, MILAN BLAKE
-
Patent number: 8822427Abstract: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.Type: GrantFiled: October 23, 2012Date of Patent: September 2, 2014Assignee: HarrisvaccinesInventors: John Dustin Loy, Lyric Colleen Bartholomay, Delbert Linn Harris, Ed Scura, Kurt Iver Kamrud
-
Patent number: 8822759Abstract: The present invention relates to transcriptional control sequences derived from GL9 genes, wherein the transcriptional control sequences direct specific or preferential expression of an operably connected nucleotide sequence of interest in one or more parts of a plant seed.Type: GrantFiled: March 18, 2011Date of Patent: September 2, 2014Assignee: Australian Centre for Plant Functional Genomics Pty. Ltd.Inventors: Sergiy Lopato, Nataliya Kovalchuk
-
Patent number: 8822666Abstract: The present invention relates to novel hybrid promoters comprising a caulimovirus promoter operably linked to one or more of an EF1?, Act8, Act2 or Act11 promoter. The present invention also relates to novel DNA constructs comprising at least one expression cassette which comprises the hybrid promoter thereof. The present invention further relates to transgenic plants/seeds comprising such DNA constructs.Type: GrantFiled: November 28, 2012Date of Patent: September 2, 2014Assignee: Monsanto Technology LLCInventors: Karen L. Fincher, Stanislaw Flasinski, Jack Q. Wilkinson
-
Publication number: 20140243203Abstract: Compositions and methods relating to the use of sulfonylurea-mediated control of gene expression are provided. Compositions include sulfonylurea responsive chemical switches wherein the gene expression is regulated by a sulfonylurea compound. Compositions also include polynucleotides encoding the polypeptides as well as constructs, vectors, prokaryotic and eukaryotic cells, and eukaryotic organisms including plants and seeds comprising the polynucleotide, and/or produced by the methods. Also provided are methods to regulate expression of a polynucleotide of interest in a cell or organism, and methods to modify a genome, including in a plant or plant cell.Type: ApplicationFiled: February 27, 2014Publication date: August 28, 2014Applicants: PIONEER HI-BRED INTERNATIONAL INC, E I DU PONT DE NEMOURS AND COMPANYInventors: JIN FANG, William Gordon-Kamm, Keith Lowe, Kevin E. McBride, Brian McGonigle, Carl Simmons
-
Publication number: 20140242636Abstract: A method of producing a protein of interest (POI) by culturing a recombinant eukaryotic cell line comprising an expression construct comprising a regulatable promoter and a nucleic acid molecule encoding a POI under the transcriptional control of said promoter, comprising the steps a) cultivating the cell line with a basal carbon source repressing the promoter, b) cultivating the cell line with a limited amount of a supplemental carbon source de-repressing the promoter to induce production of the POI at a transcription rate of at least 15% as compared to the native pGAP promoter, and c) producing and recovering the POI; and further an isolated regulatable promoter and a respective expression system.Type: ApplicationFiled: October 5, 2012Publication date: August 28, 2014Applicant: LONZA LTD.Inventors: Diethard Mattanovich, Brigitte Gasser, Michael Maurer, Roland Prielhofer, Joachim Klein, Jana Wenger
-
Patent number: 8816059Abstract: The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-?N, and inhibitors of CPE-?N and compositions thereof.Type: GrantFiled: January 14, 2011Date of Patent: August 26, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Yoke-peng Loh, Niamh X. Cawley, Saravana Radha Krishna Murthy, Terence K. Lee
-
Patent number: 8815819Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.Type: GrantFiled: September 12, 2011Date of Patent: August 26, 2014Assignee: Coda Therapeutics, Inc.Inventors: Wilda Laux, Colin Richard Green
-
Patent number: 8816152Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.Type: GrantFiled: June 20, 2012Date of Patent: August 26, 2014Assignee: Monsanto Technology LLCInventors: Tedd D. Elich, Philip N. Benfey, Ai-Jiuan Wu, David A. Orlando, Ian Davis
-
Patent number: 8816061Abstract: A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.Type: GrantFiled: March 14, 2013Date of Patent: August 26, 2014Assignee: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State UniversityInventors: James C. Carrington, Edwards Allen
-
Patent number: 8815779Abstract: This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response.Type: GrantFiled: September 16, 2009Date of Patent: August 26, 2014Assignee: SwitchGear Genomics, Inc.Inventors: Shelley Force Aldred, Nathan D. Trinklein, Michael Rose, Patrick Collins
-
Patent number: 8816056Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.Type: GrantFiled: March 30, 2012Date of Patent: August 26, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
-
Patent number: 8815568Abstract: The invention provides eukaryotic unicellular algae engineered to express a nucleosome alteration protein fused to a protein with affinity to the DNA binding site acting in coordination. An example is a LexA-p300 fusion protein, where the p300 is derived from Chlamydomonas. The LexA binding domain guides the p300 to the binding site and the p300 loosens the nucleosome structure by acetylating histones within proximity of the transgene, thus remodeling the local chromatin structure to allow for high-level expression.Type: GrantFiled: June 25, 2013Date of Patent: August 26, 2014Assignee: Synaptic Research, LLCInventors: George Oyler, Julian Rosenberg
-
Patent number: 8816153Abstract: Recombinant DNA constructs, for use in plants and plant cells, have site-specific recombination sites that allow assessing phenotypes and modes of action by over expression or suppression of endogenous genes. In an aspect, a single DNA construct can be switched between over expression and suppression by the action of a recombinase such as the Cre recombinase on constructs having lox recombination sites. Other useful recombination systems include the Flp/frt system, the R/Rs system, the Dre/rox system, and the GIN/gix system.Type: GrantFiled: August 27, 2010Date of Patent: August 26, 2014Assignee: Monsanto Technology LLCInventors: Larry A. Gilbertson, Shihshieh Huang, Thomas Malvar
-
Patent number: 8816060Abstract: The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.Type: GrantFiled: November 13, 2012Date of Patent: August 26, 2014Assignee: Rockefeller UniversityInventors: Thomas H. Tuschl, Markus Landthaler, Gunter Meister, Sebastien Pfeffer
-
Publication number: 20140237685Abstract: Methods and compositions that affect grain shape, width, and yield in rice are disclosed. Methods of transgenic modulation and marker-assisted breeding methods improve grain length to width ratio and grain yield in rice. Down-regulation of OsSPL16 in rice resulted in increased grain quality.Type: ApplicationFiled: September 19, 2012Publication date: August 21, 2014Inventors: Xiangdong Fu, Shaokui Wang, Kun Wu, Guiquan Zhang, Ruizhen Zeng
-
Publication number: 20140237682Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.Type: ApplicationFiled: July 18, 2012Publication date: August 21, 2014Inventors: Tedd D. Elich, Philip N. Benfey, Ian Davis
-
Patent number: 8809017Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.Type: GrantFiled: May 24, 2012Date of Patent: August 19, 2014Assignee: Agency for Science, Technology and ResearchInventors: Yuansheng Yang, Steven Ho, Jia Juan Lee
-
Patent number: 8809289Abstract: A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes.Type: GrantFiled: September 10, 2010Date of Patent: August 19, 2014Assignees: Saitama Medical University, RNAi Co., Ltd.Inventors: Satoshi Inoue, Ikeda Kazuhiro
-
Patent number: 8809628Abstract: The present invention provides non-coding regulatory element polynucleotide molecules isolated from the S-adenosyl methionine synthetase (SAMS3) gene of Arabidopsis thaliana and useful for expressing transgenes in plants. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the Arabidopsis thaliana regulatory polynucleotide sequences, and methods for preparing and using the same.Type: GrantFiled: May 17, 2010Date of Patent: August 19, 2014Assignee: Monsanto Technology LLCInventors: Wei Wu, Qi Wang, Michael Edgerton, Kim Beazley, Jill Deikman, Michael W. Petersen, Bei Zhang
-
Patent number: 8809626Abstract: Trichome specific plant promoters are provided herein. Also provided are transgenic cells and organisms, especially plant cell and plants, comprising an trichome specific promoter and methods for expressing nucleic acid sequences in cells and organisms using trichome specific promoters.Type: GrantFiled: December 16, 2008Date of Patent: August 19, 2014Assignee: KeyGene N.V.Inventors: Petronella Martina Bleeker, Christianus Cornelis Nicolaas Van Schie, Paul Johan Diergaarde, Robert Cornelis Schuurink, Michel Albertus Haring, Michiel Theodoor Jan De Both
-
Publication number: 20140230093Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.Type: ApplicationFiled: July 18, 2012Publication date: August 14, 2014Inventors: Tedd D. Elich, Philip N. Benfey, Ian Davis, David A. Orlando
-
Patent number: 8802921Abstract: A method for producing a transgenic plant includes providing a nucleic acid molecule comprising at least two regions of nucleic acid sequence that lack sequence homology with genomic DNA of the plant cell, and at least two zinc finger nuclease recognition sites, wherein the at least two regions of nucleic acid sequence that lack sequence homology with genomic DNA of the plant cell flank the at least two zinc finger nuclease recognition sites. A plant cell or tissue having the nucleic acid molecule stably integrated into the genome of the plant cell is transformed. A plant is regenerated from the plant cell. Transgenic plants are produced by the method. Seeds are produced by the transgenic plants.Type: GrantFiled: January 21, 2011Date of Patent: August 12, 2014Assignee: Dow AgroSciences, LLC.Inventors: William M. Ainley, Ryan C. Blue, Michael G. Murray, David Corbin, Rebecca R. Miles, Steven R. Webb
-
Patent number: 8802928Abstract: The present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a Yield Enhancing Protein (YEP). The YEP is selected from a Nucleosome Assembly Protein 1-like polypeptide (NAP1-like), a Like Sm polypeptide (Lsm protein), a truncated Cyclin H (CycHTr) polypeptide, a Remorin polypeptide, and a DREB protein. The present invention also concerns plants having modulated expression of a nucleic acid encoding such a YEP, which plants have enhanced yield-related traits relative to control plants. The invention also provides hitherto unknown YEP-encoding nucleic acids, and constructs comprising the same, useful in performing the methods of the invention.Type: GrantFiled: January 31, 2008Date of Patent: August 12, 2014Assignee: BASF Plant Science GmbHInventors: Ana Isabel Sanz Molinero, Valerie Frankard, Yves Hatzfeld, Christophe Reuzeau
-
Patent number: 8802080Abstract: Disclosed are improved recombinant adeno-associated viral (rAAV) vectors having mutations in one or more capsid proteins. Exemplary vectors are provided that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations that comprise them useful in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.Type: GrantFiled: May 1, 2003Date of Patent: August 12, 2014Assignee: University of Florida Research Foundation, Inc.Inventors: Kenneth H. Warrington, Shaun R. Opie, Nicholas Muzyczka
-
Patent number: 8802645Abstract: The invention provides two types of oligonucleotides for treating an inflammatory disorder: an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a and an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a IL-1RAcP in order to increase the amount of a soluble IL-1RAcP. The invention further provides the use of said oligonucleotides for preventing or treating an inflammatory disorder.Type: GrantFiled: June 21, 2012Date of Patent: August 12, 2014Assignees: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden H.O.D.N. LUMCInventors: Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus, Judith Christina Theodora Van Deutekom, Josephus Johannes De Kimpe, Joseph Stephan Verbeek, Aliye Seda Ylmaz-Elis
-
Patent number: 8802648Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases.Type: GrantFiled: December 4, 2012Date of Patent: August 12, 2014Inventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale
-
Publication number: 20140220632Abstract: The present disclosure generally provides non-naturally-occurring polynucleotide sequences that facilitate high-level expression of one or more gene products (e.g., polypeptides, RNA) of interest in Neisseria meningitidis. Methods of use of such sequences, e.g., use in vaccine production, are also provided.Type: ApplicationFiled: August 30, 2012Publication date: August 7, 2014Applicant: Children's Hospital & Research Center OaklandInventor: Rolando Pajon Feyt
-
Patent number: 8796444Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: GrantFiled: July 6, 2011Date of Patent: August 5, 2014Assignees: City of Hope, Integrated DNA Technologies, Inc.Inventors: John J. Rossi, Mark A. Behlke, Dongho Kim
-
Patent number: 8796507Abstract: The present invention relates to promoters that enable gene expression which is both specific to the endosperm and early during the development of the endosperm, as well as nucleic acid molecules encoding basal endosperm transfer cell layer (BETL) proteins.Type: GrantFiled: April 1, 2011Date of Patent: August 5, 2014Assignee: BiogemmaInventors: Pascual Perez, José Gutierrez-Marcos, Hugh Dickinson
-
Patent number: 8795675Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.Type: GrantFiled: December 20, 2012Date of Patent: August 5, 2014Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
-
Patent number: 8796440Abstract: The present invention is directed to a bidirectional human cytomegalovirus (hCMV) promoter that can be used to promote transcription on both strands of a double stranded DNA molecule. When used as part of a system that includes tet operator and the gene coding for the tet repressor, the promoter can be used to induce mammalian gene expression in a highly regulated way.Type: GrantFiled: August 20, 2010Date of Patent: August 5, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventor: Feng Yao
-
Patent number: 8795965Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: GrantFiled: February 18, 2014Date of Patent: August 5, 2014Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventor: Feng Zhang
-
Publication number: 20140213779Abstract: The present invention relates to a system comprising a genetic construct a riboswitch operably linked to a regulatory sequence, and a second genetic construct a coding sequence whose expression is capable of being regulated by a gene product of the first construct. Also provided is a genetic construct comprising one or more riboswitches for regulation of gene expression, wherein preferably a spacer sequence is provided downstream of the riboswitch to enhance expression of a coding sequence which is operably linked to a riboswitch. Ligands, kits, methods, host cells and expression systems are also provided.Type: ApplicationFiled: May 10, 2012Publication date: July 31, 2014Applicant: THE UNIVERSITY OF MANCHESTERInventors: Neil Dixon, Jason Micklefield
-
Patent number: 8790896Abstract: The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermore, it relates to nucleic acid sequences exhibiting a reduced number of RNase L cleavage sites as well as to the proteins translated from such sequences.Type: GrantFiled: January 19, 2010Date of Patent: July 29, 2014Assignees: King Faisal Specialist Hospital & Research Centre, Terramark Markencreation GmbHInventor: Khalid S. Khabar
-
Patent number: 8791248Abstract: A method of preparing induced pluripotent stem cells, comprising a nuclear reprogramming step with a nuclear reprogramming factor in the presence of miRNA, wherein said miRNA has a property of providing a higher nuclear reprogramming efficiency in the presence of said miRNA than in the absence thereof.Type: GrantFiled: December 7, 2011Date of Patent: July 29, 2014Assignee: Kyoto UniversityInventors: Shinya Yamanaka, Michiyo Koyanagi
-
Patent number: 8791325Abstract: The invention provides for identification and use of certain chloroplast transit peptides for efficient processing and localization of dicamba monooxygenase (DMO) enzyme in transgenic plants. Methods for producing dicamba tolerant plants, methods for controlling weed growth, and methods for producing food, feed, and other products are also provided, as well as seed that confers tolerance to dicamba when it is applied pre- or post-emergence.Type: GrantFiled: February 22, 2013Date of Patent: July 29, 2014Assignee: Monsanto Technology LLCInventors: Paul C. C. Feng, Marianne Malven, Stanislaw Flasinski
-
Patent number: 8791330Abstract: The present invention relates generally to an expression regulatory element operable in plants which includes oil palm, and in particular to an expression regulatory element operable selectively in the endosperm tissue of the plants. Said expression regulatory element comprises a sequence of nucleotides which specifically modulates the expression of a second nucleic acid molecule operably coupled to said expression regulatory element.Type: GrantFiled: March 13, 2008Date of Patent: July 29, 2014Assignee: Malaysian Palm Oil BoardInventors: Siti Nor Akmar Abdullah, Suan Choo Cheah, Nurniwalis Abd. Wahab